Background
ASTRO Evidence-Based Clinical Practice Guideline for oropharyngeal squamous cell carcinoma (OPSCC). Systematic literature review by the ASTRO OPSCC Guideline Panel addressing four key questions: (1) when to add systemic therapy to definitive RT; (2) when to deliver postoperative RT with/without systemic therapy; (3) when to use induction chemotherapy; (4) appropriate dose, fractionation, and target volume. Evidence graded using GRADE. Published in Practical Radiation Oncology 2017.
Interventions and follow up
Design: ASTRO evidence-based clinical practice guideline; systematic literature review addressing four key questions on definitive and adjuvant RT for oropharyngeal SCC
Primary endpoint: Consensus recommendations graded by evidence quality
mFollow up: Not applicable
Primary endpoint: Consensus recommendations graded by evidence quality
mFollow up: Not applicable
Results
Summary: Evidence-based guideline, not a prospective trial; key recommendations synthesized from randomized data
Definitive RT + systemic therapy: Stage IV and T3N0-1 OPSCC → concurrent high-dose intermittent cisplatin (strong recommendation)
Post-op RT + systemic therapy: Positive margins or ECE → concurrent cisplatin; not routinely for other risk factors
Induction chemotherapy: NOT routinely recommended
Altered fractionation: For patients ineligible for concurrent CRT
Definitive RT + systemic therapy: Stage IV and T3N0-1 OPSCC → concurrent high-dose intermittent cisplatin (strong recommendation)
Post-op RT + systemic therapy: Positive margins or ECE → concurrent cisplatin; not routinely for other risk factors
Induction chemotherapy: NOT routinely recommended
Altered fractionation: For patients ineligible for concurrent CRT
Adverse events
Toxicity emphasis: concurrent CRT burden — mucositis, dysphagia, xerostomia, nephrotoxicity; systemic therapy endorsed only when benefit clearly outweighs risk
Cisplatin-ineligible: cetuximab or carboplatin regimens discussed but noted as lower evidence base
Cisplatin-ineligible: cetuximab or carboplatin regimens discussed but noted as lower evidence base
Conclusions
The ASTRO 2017 guideline established evidence-based indications for concurrent cisplatin in definitive and adjuvant OPSCC RT, recommended against routine induction chemotherapy, and endorsed altered fractionation for cisplatin-ineligible patients. Formalized clinical decision-making for the HPV era while awaiting de-escalation trial results.
Key Limitations
Guideline, not a prospective trial; recommendations limited by quality of underlying evidence. Predates mature HPV de-escalation trial results; HPV status not incorporated into systemic-therapy decisions.
Clinical Context
Aligns with ASCO/ESMO positioning of concurrent cisplatin-RT as standard for high-risk OPSCC; cetuximab-RT is inferior to cisplatin-RT in HPV+ disease (per subsequent RTOG 1016/De-ESCALaTE), reinforcing cisplatin preference.